Total
0
Shares
PYC Therapeutics (ASX:PYC) - CEO, Dr Rohan Hockings
CEO, Dr Rohan Hockings
Source: Business News
Market Herald logo

Subscribe

Be the first with the news that moves the market
  • PYC Therapeutics (PYC) has made a significant breakthrough in the treatment of retinitis pigmentosa-11 — a degenerative eye disease
  • PYC’s lead investigation drug, VP-001, has been shown to restore function of the retinal pigment epithelium (RPE), which is a crucial structure for preventing fluid leaking into and damaging the retina
  • Importantly, the drug is the first and only treatment to demonstrate restoration of the RPE in a patient-derived model
  • The biotech company is now progressing further studies ahead of submitting an Investigational New Drug application to the U.S. Food and Drug Administration next year
  • PYC is up 3.45 per cent and shares are trading at 15 cents

PYC Therapeutics’ (PYC) lead investigational drug, VP-001, has demonstrated a key functional improvement in patient-derived models of retinitis pigmentosa-11 (RP11).

VP-001 is being developed to treat RP11 , a retinal degenerative disease that often leads to legal and, sometimes, complete blindness.

The functional improvement is that VP-001 has restored function of the retinal pigment epithelium (RPE), which is a critical cell layer that forms the outer blood-retinal barrier and prevents fluid from leaking into and damaging the retina.

“The individual RPE cells act like bricks in a dam; they all work together in stopping large amounts of fluid flowing directly into the retina. At the same time, they allow for the controlled flow of nutrients to keep the retina functioning and enable normal vision,” Chief Scientific Officer Professor Sue Fletcher said.

Significantly, VP-001 is the first and only treatment to demonstrate restoration of the retinal pigment epithelium in a patient-derived model.

“This result has given us the best non-clinical demonstration that VP-001 has the potential to correct this problem in patients,” U.S. CEO Sahm Nasseri said.

PYC will continue sharing the VP-001 drug’s progress through large animal studies later this year. Its goal is to submit an Investigational New Drug application to the U.S. Food and Drug Administration in the first half of next year.

PYC is up 3.45 per cent and shares are trading at 15 cents at 12:45 pm AEDT.

PYC by the numbers
More From The Market Herald
APM (ASX:APM) - CEO, Michael Anghie

" APM Human Services (ASX:APM) expands, acquiring Lifecare

APM Human Services International (APM) has acquired physiotherapy and home care group Lifecare for $68 million.
Resonance Health (ASX:RHT)

" Resonance Health (ASX:RHT) submits LiverSmart to FDA

Resonance Health (RHT) has submitted its LiverSmart device to the Food and Drug Administration (FDA) for US regulatory clearance.
Dotz Nano (ASX:DTZ) - CEO, Gideon Shmuel

" Dotz Nano (ASX:DTZ) signs Malaysian distribution deal for COVID-19 tests

Dotz Nano (DTZ) has entered into a distribution agreement with ScienceVision to promote, sell and distribute its COVID-19 virus detection technology in Malaysia.
Kazia Therapeutics (ASX:KZA) - CEO, Dr James Garner

" Kazia Therapeutics (ASX:KZA) releases “positive” second-phase study results for brain cancer treatment

Kazia Therapeutics (KZA) has opened the trading day green after reporting positive final results from a second-phase clinical study of its paxalisib drug